| Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer |
876 |
| Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes |
780 |
| Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy |
720 |
| Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients |
719 |
| Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma |
637 |
| Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction |
635 |
| Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia |
617 |
| Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer |
608 |
| Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct |
603 |
| Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer |
594 |
| Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients |
570 |
| Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging |
545 |
| Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC |
544 |
| Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer |
543 |
| Immune-Related Adverse Events Associated with Immune Checkpoint Blockade |
504 |
| Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden |
482 |
| Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma |
463 |
| Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC |
459 |
| Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
422 |
| Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia |
414 |
| First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer |
406 |
| Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma |
400 |
| Hepatocellular Carcinoma |
390 |
| Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome |
385 |
| MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis |
381 |
| Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma |
373 |
| A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics |
370 |
| Transcatheter Mitral-Valve Repair in Patients with Heart Failure |
362 |
| Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia |
358 |
| Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer |
348 |
| Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis |
343 |
| FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer |
296 |
| Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts |
295 |
| Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer |
294 |
| Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer |
292 |
| Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma |
290 |
| Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma |
287 |
| Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children |
280 |
| Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy |
279 |
| A Randomized Trial of E-Cigarettes versus Nicotine-Replacement Therapy |
276 |
| Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer |
270 |
| Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer |
262 |
| Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer |
252 |
| Chimeric Antigen Receptor Therapy |
251 |
| Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction |
247 |
| Multiple Sclerosis |
247 |
| Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome |
246 |
| Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation |
245 |
| Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer |
236 |
| Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction |
233 |
| Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease |
229 |
| Catheter Ablation for Atrial Fibrillation with Heart Failure |
227 |
| Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma |
224 |
| Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation |
223 |
| Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism |
223 |
| Neoadjuvant PD-1 Blockade in Resectable Lung Cancer |
218 |
| Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma |
217 |
| Machine Learning in Medicine |
215 |
| Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML |
208 |
| Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain |
205 |
| Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma |
204 |
| PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma |
200 |
| Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes |
199 |
| Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation |
197 |
| Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma |
196 |
| Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis |
193 |
| Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection |
191 |
| Low-Dose Methotrexate for the Prevention of Atherosclerotic Events |
187 |
| Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer |
178 |
| Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma |
176 |
| Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease |
176 |
| Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer |
175 |
| Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer |
173 |
| Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes |
167 |
| Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma |
167 |
| Nintedanib in Progressive Fibrosing Interstitial Lung Diseases |
162 |
| Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus |
161 |
| Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer |
160 |
| Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma |
156 |
| Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer |
155 |
| Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL |
155 |
| Coronary CT Angiography and 5-Year Risk of Myocardial Infarction |
154 |
| Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy |
153 |
| Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele |
152 |
| Ambient Particulate Air Pollution and Daily Mortality in 652 Cities |
151 |
| Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma |
149 |
| Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly |
149 |
| Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer |
149 |
| Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer |
149 |
| Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant |
148 |
| Idiopathic Pulmonary Fibrosis |
147 |
| Duration of Adjuvant Chemotherapy for Stage III Colon Cancer |
147 |
| Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer |
146 |
| Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation |
145 |
| Global, Regional, and Country-Specific Lifetime Risks of Stroke, 1990 and 2016 |
144 |
| Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer |
144 |
| Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer |
143 |
| Apixaban to Prevent Venous Thromboembolism in Patients with Cancer |
142 |
| Ticagrelor with or without Aspirin in High-Risk Patients after PCI |
142 |
| CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma |
141 |
| MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset |
140 |
| Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents |
140 |
| Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer |
136 |
| Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure |
133 |
| Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD |
133 |
| Early Neuromuscular Blockade in the Acute Respiratory Distress Syndrome |
132 |
| Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease |
132 |
| Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer |
130 |
| Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions |
130 |
| Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML |
130 |
| Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome |
129 |
| Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia |
128 |
| Labor Induction versus Expectant Management in Low-Risk Nulliparous Women |
127 |
| Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer |
127 |
| Survival after Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer |
127 |
| Changes in Prevalence of Health Care-Associated Infections in US Hospitals |
127 |
| Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer |
127 |
| Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes |
126 |
| Balanced Crystalloids versus Saline in Critically Ill Adults |
126 |
| Complete Revascularization with Multivessel PCI for Myocardial Infarction |
125 |
| Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer |
125 |
| Antibody-Mediated Encephalitis |
124 |
| Five-Year Outcomes with PCI Guided by Fractional Flow Reserve |
123 |
| Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors |
122 |
| Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma |
121 |
| Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA |
121 |
| A Fully Magnetically Levitated Left Ventricular Assist Device - Final Report |
118 |
| Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source |
118 |
| Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia |
117 |
| Effects of Intermittent Fasting on Health, Aging, and Disease |
117 |
| Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy |
117 |
| Prevention of M-tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination |
116 |
| Two-Year Outcomes with a Magnetically Levitated Cardiac Pump in Heart Failure |
113 |
| Effect of Aspirin on All-Cause Mortality in the Healthy Elderly |
112 |
| Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis |
111 |
| Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke |
110 |
| Adjunctive Glucocorticoid Therapy in Patients with Septic Shock |
109 |
| Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease |
108 |
| Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus |
106 |
| Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer |
104 |
| Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma |
103 |
| Targeting Huntingtin Expression in Patients with Huntington's Disease |
103 |
| Oral versus Intravenous Antibiotics for Bone and Joint Infection |
103 |
| Application of Cell-free DNA Analysis to Cancer Treatment |
103 |
| Projected US State-Level Prevalence of Adult Obesity and Severe Obesity |
103 |
| A Randomized Trial of Epinephrine in Out-of-Hospital Cardiac Arrest |
102 |
| A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease |
101 |
| Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source |
101 |
| Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout |
101 |
| Circulating Extracellular Vesicles in Human Disease |
99 |
| Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura |
99 |
| Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder |
98 |
| Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma |
98 |
| Clinical Metagenomic Sequencing for Diagnosis of Meningitis and Encephalitis |
97 |
| Molecular Minimal Residual Disease in Acute Myeloid Leukemia |
96 |
| Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors |
95 |
| Restrictive versus Liberal Fluid Therapy for Major Abdominal Surgery |
95 |
| Vitamin D Supplementation and Prevention of Type 2 Diabetes |
95 |
| Hydrocortisone plus Fludrocortisone for Adults with Septic Shock |
94 |
| AR101 Oral Immunotherapy for Peanut Allergy |
92 |
| An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes |
91 |
| VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles |
91 |
| Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease |
90 |
| Ibrutinib and Venetoclax for First-Line Treatment of CLL |
90 |
| Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease |
90 |
| Acceleration of BMI in Early Childhood and Risk of Sustained Obesity |
90 |
| Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis |
88 |
| Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma |
88 |
| Magnetic Resonance Perfusion or Fractional Flow Reserve in Coronary Disease |
88 |
| Inhaled Combined Budesonide-Formoterol as Needed in Mild Asthma |
88 |
| Prehospital Plasma during Air Medical Transport in Trauma Patients at Risk for Hemorrhagic Shock |
87 |
| Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol |
85 |
| A Genotype-Guided Strategy for Oral P2Y(12) Inhibitors in Primary PCI |
85 |
| Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV |
85 |
| Helicobacter pylori Therapy for the Prevention of Metachronous Gastric Cancer |
83 |
| The Major Causes of Death in Children and Adolescents in the United States |
82 |
| Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes |
82 |
| As-Needed Budesonide-Formoterol versus Maintenance Budesonide in Mild Asthma |
81 |
| Recurrent Glioblastoma Treated with Recombinant Poliovirus |
81 |
| Classification and Personalized Prognosis in Myeloproliferative Neoplasms |
81 |
| The Key Role of Epigenetics in Human Disease Prevention and Mitigation |
80 |
| Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis |
79 |
| Primary Sjogren's Syndrome |
79 |
| Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma |
78 |
| Discrimination, Abuse, Harassment, and Burnout in Surgical Residency Training |
77 |
| Diagnosis and Management of the Antiphospholipid Syndrome |
76 |
| Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma |
76 |
| Timing of Renal-Replacement Therapy in Patients with Acute Kidney Injury and Sepsis |
76 |
| Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer |
76 |
| The All of Us Research Program |
75 |
| Gene Therapy in Patients with Transfusion-Dependent beta-Thalassemia |
75 |
| Phase 2b Controlled Trial of M72/AS01(E) Vaccine to Prevent Tuberculosis |
75 |
| Relationship between Clinic and Ambulatory Blood-Pressure Measurements and Mortality (Retracted article. See vol. pg. 2020) |
74 |
| Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma |
73 |
| Radical Prostatectomy or Watchful Waiting in Prostate Cancer-29-Year Follow-up |
73 |
| Targeted Temperature Management for Cardiac Arrest with Nonshockable Rhythm |
73 |
| Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer |
73 |
| Mortality in Puerto Rico after Hurricane Maria |
72 |
| Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients |
72 |
| Gene Therapy |
71 |
